BioSpace News Archive

Visby Medical™, an infectious disease diagnostic company, received Phase 2 funding from the National Institutes of Health (NIH) as part of its Rapid Acceleration of Diagnostics (RADx) initiative. The RADx initiative aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.

Company to present Phase 1 safety, tolerability and TRPC5-Rac1 pathway target engagement data at American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting -- -- Additional poster presentations to showcase GFB-887’s novel urinary Rac1 predictive biomarker strategy and company’s proprietary precision medicine platform -- -- Kidney and Cardio-Metabolic R&D expert, Gus Gustafson, Ph.D., joins Goldfinch Bio as Senior Vice Presiden

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO

Regulus Therapeutics Inc . (Nasdaq: RGLS) (the “Company” or “Regulus”), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced receipt of a total of $5 million in mi

Spinal cord stimulation systems are used to modulate the nervous system to improve biological functioning of spinal cord.

Cigna’s International Markets business published the third edition of its COVID-19 Global Impact Study, which sheds new light on the impact of the virus on global perceptions of health and well-being.

A pharmaceutical isolator provides continuous isolation to interior from external environment.

The global outpatient home therapy market is gaining traction owing to the convenience it provides to patients.

EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced the successful completion of a RMB 450 million Series B financing.

First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix